PDEX
Pro-Dex, Inc.44.70
+0.90+2.05%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
146.62MP/E (TTM)
13.46Basic EPS (TTM)
3.32Dividend Yield
0%Recent Filings
8-K
Pro-Dex acquires APM for $8.65M
Pro-Dex closed its $8.65M acquisition of Advanced Precision Machining on February 9, 2026, paying $6.65M cash funded by a new UMB term loan and issuing a $2M subordinated note at 8% over 63 months. APM, a long-time supplier, makes Pro-Dex sub-assemblies plus aerospace/defense parts with ITAR/JCP certifications. Deal supports expansion amid major customer growth, yet adds debt load.
8-K
Q2 sales up 11%, profit surges
Pro-Dex posted Q2 fiscal 2026 net sales of $18.7M, up 11% from $16.8M, fueled by $7.3M in next-gen orthopedic handpieces from its largest customer despite legacy declines. Gross margin ticked to 31%; operating income rose 21% to $3.3M. Six-month net income hit $6.9M, boosted by a $6.8M Monogram gain. Acquisition of key supplier looms for capacity.
10-Q
Q2 FY2026 results
Pro-Dex posted solid Q2 FY2026 momentum, with net sales up 11% y/y to $18.7M and 17% y/y for the half to $37.2M, driven by 27% y/y orthopedic growth from a key customer's next-gen handpiece launch while repairs fell 35% y/y. Gross margin ticked up 1 ppt y/y to 31%; operating income rose 21% y/y to $3.3M, diluted EPS climbed to $0.66 (reconciles to 3.3M shares). Cash swelled to $8.0M on $5.9M operating cash flow, fueled by a $8.9M Monogram sale (net $3.0M gain YTD); debt dropped to $10.5M across fixed-rate term loans (3.55-3.84%) maturing 2027-2030, with $11M revolver available. Stock repurchases hit $2.2M. Customer concentration runs high at 88%. Volatility stalks thinly traded investments.
8-K
Contract extended; CEO bonus awarded
Pro-Dex awarded CEO Richard L. Van Kirk a $225,000 bonus on December 18, 2025, for hitting Fiscal 2024 targets. Days earlier, on December 17, it extended its contract with its largest customer through December 31, 2028, adding minimum purchase volumes for 2026-2027. This locks in revenue stability. Fifteen years strong.
8-K
Annual meeting results, comp grants
Pro-Dex held its 2025 annual meeting on November 20, electing all seven board nominees and ratifying Baker Tilly as auditors for fiscal 2026. Shareholders approved extending the 2016 Equity Incentive Plan by ten years, advisory say-on-pay, and annual frequency. Compensation Committee granted 1,000 restricted shares to CFO Alisha Charlton, vesting over five years, and a $30,830 cash bonus to CEO Richard Van Kirk. All insiders aligned.
IPO
Website
Employees
Sector
Industry
APYX
Apyx Medical Corporation
3.72-0.07
BDX
Becton, Dickinson and Company
196.39-3.70
ECIA
Encision, Inc.
0.15+0.00
IRIX
IRIDEX Corporation
1.00+0.02
ISRG
Intuitive Surgical, Inc.
554.58-4.94
PLSE
Pulse Biosciences, Inc
14.23+0.10
PRCT
PROCEPT BioRobotics Corporation
35.66-0.44
PROF
Profound Medical Corp.
7.55-0.14
RMD
ResMed Inc.
247.34-5.73
STXS
Stereotaxis, Inc.
2.38+0.06